Table 1.

Prevalence study

Number of patients	492
Median age (years, range)	53 (26–76)
Menopausal status
Postmenopausal	58%
Premenopausal	42%
Adjuvant therapy
FAC/FEC/AC/EC × 6 cycles	148
FAC/FEC/AC/EC × 4 cycles → weekly paclitaxel × 8–12 cycles	29
Epirubicin 90 mg/m2 plus docetaxel 75 mg/m2 × 4 cycles → Capecitabine × 4 cycles	31
TAC × 6 cycles	74
A/E+/−C × 4 cy → docetaxel 100 mg/m2 × 4 cycles +/−trastuzumab	66
Tamoxifena	57
Aromatase inhibitorsb	87

Characteristic of the patients and therapy (HCSC)

HCSC, Hospital Clinico San Carlos, Madrid; FAC: 5-fluorouracil, doxorubicin, cyclophosphamide; FEC, 5-fluorouracil, doxorubicin, cyclophosphamide; AC/EC, doxorubicin or epirubicin plus cyclophosphamide; TC, docetaxel 75 mg/m² plus cyclophsphamide; TAC, docetaxel 75 mg/m², doxorubicin, cyclophosphamide; TCH, docetaxel 75 mg/m², carboplatin AUC 6, trastuzumab

^aWithout prior adjuvant chemotherapy

^bWithout prior adjuvant chemotherapy; some patients included in this group have received tamoxifen followed by an aromatase inhibitor